01
Why it is on pain menus
Innate-repair-receptor ideas made it a research celebrity. Celebrity is not a vial.
- ·Neuropathic-pain research interest
- ·Not a diagnosis of your nerve pain
- ·Not orderable
RE GEN RX · peptides / ARA-290
No lawful pathway
ARA-290
An EPO-derived peptide in neuropathic-pain marketing — no lawful §503A pathway.
Oswego, Illinois · 74 W. Washington St · serving the Fox Valley. A licensed Illinois clinician still decides. Compounded medications are not FDA-approved.
Legal status reviewed July 2026 · Course set at consult
What is ARA-290?
The molecule, in plain language.
ARA-290 (cibinetide) is derived from erythropoietin structure and studied for neuropathic pain and tissue-protection research. It is not something RE GEN can lawfully compound today, and we will not treat this page as pain-clinic advertising.
How people usually take it. Not orderable.
What people are actually trying to solve.
Interest is not a result. We keep the research language and skip the miracle.
02
Pain is not a peptide we will fake
If you are in pain, you need appropriate evaluation. We will not gray-market ARA-290 while you wait.
- ·Consult for carried options
- ·No promised pain score
- ·Emergency symptoms need emergency care
03
Curcumin injectable is a different card
That is a clinician-directed anti-inflammatory conversation with a different legal file.
- ·Curcumin page
- ·Not interchangeable
- ·Clinician decides
What the evidence actually is — and what it isn’t.
A note on honesty: we will tell you what the literature supports and what it does not. Animal data is not a human guarantee. Anecdotes are not trials.
Animal research
ARA-290 has preclinical neuropathic and tissue-protection literature.
- ·Not 503A eligibility here
- ·Not orderable
- ·Not a pain cure
Human research
Human development exists in other lanes. It does not open compounding at RE GEN.
- ·Not orderable
- ·No neuropathic-pain guarantee
- ·Do not buy research ARA-290
Legal basis at RE GEN · July 2026
We will not compound this today.
No lawful §503A pathway at this time. We will not compound ARA-290.
We will not compound this. Ask us what is carried instead.
Common questions
Peptide education for Illinois patients at RE GEN in Oswego — not a substitute for a visit.
What is ARA-290?
Cibinetide — an EPO-derived peptide studied in neuropathic-pain research. Not orderable at RE GEN.
Is ARA-290 FDA-approved?
ARA-290 is not FDA-approved, and RE GEN does not have a lawful §503A pathway to request it as a compounded medication today. A committee vote is not approval.
Can I get ARA-290 at RE GEN in Oswego?
You can start a visit to talk about your goal. We will not compound ARA-290 today. We will show you what is carried instead — and we will say no rather than gray-market a vial.
Can you help with pain another way?
Start a visit or consult. We will not compound ARA-290. A clinician can talk about what is carried.
Do you promise results?
No. Educational pages explain why people ask and what the research landscape looks like. Individual response varies. Compounded medications are not FDA-approved, and a request is not a guaranteed prescription.
Related on this menu
Illinois practice · licensed 503A compounding
We will tell you no — and show you what is carried instead.
Hello Gorgeous PC · 74 W. Washington St, Oswego, IL
RE GEN desk 630-636-6193
Start a visit, a licensed Illinois clinician reviews, then you pay the invoice. If they don't prescribe, we refund.